Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Story summaryNovartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market, the Swiss pharmaceutical giant said Friday.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.